H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating

Published 23/07/2025, 13:44
H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating

Investing.com - H.C. Wainwright initiated coverage on Maze Therapeutics (NASDAQ:MAZE) Wednesday with a Buy rating and a price target of $34.00, citing the potential of the company’s kidney disease treatment. According to InvestingPro data, the company maintains strong financial health with a "GREAT" overall score, supported by robust liquidity metrics and a current ratio of 16.1x.

The research firm highlighted MZE782, a first-in-class SLC6A19 small molecule inhibitor for chronic kidney disease (CKD), as a potential "game changer" for the stock. Phase 1 proof-of-concept data for this treatment is expected in the third quarter of 2025. The company’s strong balance sheet position, with more cash than debt and a low debt-to-equity ratio of 0.09, provides financial flexibility to advance its clinical programs.

H.C. Wainwright noted that Maze’s proprietary COMPASS platform transforms human genetic variant information into mechanism-based drug programs, positioning the company as a leader in precision nephrology while expanding pipeline potential in other indications.

The firm estimates MZE782 represents a potential market opportunity of $1.4 billion or more. The treatment is considered "derisked" based on data from similar compounds showing that blocking the SLC6A19 channel can reduce blood phenylalanine and other amino acids relevant to kidney disease.

H.C. Wainwright believes Maze Therapeutics is currently undervalued, pointing to strong human genetics evidence supporting the SLC6A19 approach, the differentiated design based on the D173N variant, and robust preclinical data as reasons for its bullish outlook. This assessment aligns with broader analyst consensus, as tracked by InvestingPro, showing a strong buy recommendation with price targets ranging from $17 to $28 per share.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.